Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
RNAi for Therapeutic Consumption market report explains the definition, types, applications, major countries, and major players of the RNAi for Therapeutic Consumption market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Mirna Therapeutics
RXi Pharmaceuticals
Sirnaomics
miRagen Therapeutics
Alnylam Pharmaceuticals
Dicerna Pharmaceuticals
Arrowhead
Gradalis
Quark Pharmaceuticals
By Type:
siRNA
miRNA
shRNA
By End-User:
Cancer
Cardiovascular
HBV
Other
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global RNAi for Therapeutic Consumption Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 RNAi for Therapeutic Consumption Outlook to 2028- Original Forecasts
-
2.2 RNAi for Therapeutic Consumption Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term RNAi for Therapeutic Consumption Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global RNAi for Therapeutic Consumption Market- Recent Developments
-
6.1 RNAi for Therapeutic Consumption Market News and Developments
-
6.2 RNAi for Therapeutic Consumption Market Deals Landscape
7 RNAi for Therapeutic Consumption Raw Materials and Cost Structure Analysis
-
7.1 RNAi for Therapeutic Consumption Key Raw Materials
-
7.2 RNAi for Therapeutic Consumption Price Trend of Key Raw Materials
-
7.3 RNAi for Therapeutic Consumption Key Suppliers of Raw Materials
-
7.4 RNAi for Therapeutic Consumption Market Concentration Rate of Raw Materials
-
7.5 RNAi for Therapeutic Consumption Cost Structure Analysis
-
7.5.1 RNAi for Therapeutic Consumption Raw Materials Analysis
-
7.5.2 RNAi for Therapeutic Consumption Labor Cost Analysis
-
7.5.3 RNAi for Therapeutic Consumption Manufacturing Expenses Analysis
8 Global RNAi for Therapeutic Consumption Import and Export Analysis (Top 10 Countries)
-
8.1 Global RNAi for Therapeutic Consumption Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global RNAi for Therapeutic Consumption Export by Region (Top 10 Countries) (2017-2028)
9 Global RNAi for Therapeutic Consumption Market Outlook by Types and Applications to 2022
-
9.1 Global RNAi for Therapeutic Consumption Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global siRNA Consumption and Growth Rate (2017-2022)
-
9.1.2 Global miRNA Consumption and Growth Rate (2017-2022)
-
9.1.3 Global shRNA Consumption and Growth Rate (2017-2022)
-
9.2 Global RNAi for Therapeutic Consumption Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Cancer Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Cardiovascular Consumption and Growth Rate (2017-2022)
-
9.2.3 Global HBV Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Other Consumption and Growth Rate (2017-2022)
10 Region and Country-wise RNAi for Therapeutic Consumption Market Analysis and Outlook till 2022
-
10.1 Global RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.2.2 Canada RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.2.3 Mexico RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.3.2 UK RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.3.3 Spain RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.3.4 Belgium RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.3.5 France RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.3.6 Italy RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.3.7 Denmark RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.3.8 Finland RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.3.9 Norway RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.3.10 Sweden RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.3.11 Poland RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.3.12 Russia RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.3.13 Turkey RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.4.2 Japan RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.4.3 India RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.4.4 South Korea RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.4.5 Pakistan RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.4.6 Bangladesh RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.4.7 Indonesia RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.4.8 Thailand RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.4.9 Singapore RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.4.10 Malaysia RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.4.11 Philippines RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.4.12 Vietnam RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.5.2 Colombia RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.5.3 Chile RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.5.4 Argentina RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.5.5 Venezuela RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.5.6 Peru RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.5.7 Puerto Rico RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.5.8 Ecuador RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.6.2 Kuwait RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.6.3 Oman RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.6.4 Qatar RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.6.5 Saudi Arabia RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.6.6 United Arab Emirates RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.7.2 South Africa RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.7.3 Egypt RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.7.4 Algeria RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia RNAi for Therapeutic Consumption Consumption (2017-2022)
-
10.8.2 New Zealand RNAi for Therapeutic Consumption Consumption (2017-2022)
11 Global RNAi for Therapeutic Consumption Competitive Analysis
-
11.1 Mirna Therapeutics
-
11.1.1 Mirna Therapeutics Company Details
-
11.1.2 Mirna Therapeutics RNAi for Therapeutic Consumption Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Mirna Therapeutics RNAi for Therapeutic Consumption Main Business and Markets Served
-
11.1.4 Mirna Therapeutics RNAi for Therapeutic Consumption Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 RXi Pharmaceuticals
-
11.2.1 RXi Pharmaceuticals Company Details
-
11.2.2 RXi Pharmaceuticals RNAi for Therapeutic Consumption Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 RXi Pharmaceuticals RNAi for Therapeutic Consumption Main Business and Markets Served
-
11.2.4 RXi Pharmaceuticals RNAi for Therapeutic Consumption Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Sirnaomics
-
11.3.1 Sirnaomics Company Details
-
11.3.2 Sirnaomics RNAi for Therapeutic Consumption Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Sirnaomics RNAi for Therapeutic Consumption Main Business and Markets Served
-
11.3.4 Sirnaomics RNAi for Therapeutic Consumption Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 miRagen Therapeutics
-
11.4.1 miRagen Therapeutics Company Details
-
11.4.2 miRagen Therapeutics RNAi for Therapeutic Consumption Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 miRagen Therapeutics RNAi for Therapeutic Consumption Main Business and Markets Served
-
11.4.4 miRagen Therapeutics RNAi for Therapeutic Consumption Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Alnylam Pharmaceuticals
-
11.5.1 Alnylam Pharmaceuticals Company Details
-
11.5.2 Alnylam Pharmaceuticals RNAi for Therapeutic Consumption Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Alnylam Pharmaceuticals RNAi for Therapeutic Consumption Main Business and Markets Served
-
11.5.4 Alnylam Pharmaceuticals RNAi for Therapeutic Consumption Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Dicerna Pharmaceuticals
-
11.6.1 Dicerna Pharmaceuticals Company Details
-
11.6.2 Dicerna Pharmaceuticals RNAi for Therapeutic Consumption Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Dicerna Pharmaceuticals RNAi for Therapeutic Consumption Main Business and Markets Served
-
11.6.4 Dicerna Pharmaceuticals RNAi for Therapeutic Consumption Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Arrowhead
-
11.7.1 Arrowhead Company Details
-
11.7.2 Arrowhead RNAi for Therapeutic Consumption Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Arrowhead RNAi for Therapeutic Consumption Main Business and Markets Served
-
11.7.4 Arrowhead RNAi for Therapeutic Consumption Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Gradalis
-
11.8.1 Gradalis Company Details
-
11.8.2 Gradalis RNAi for Therapeutic Consumption Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Gradalis RNAi for Therapeutic Consumption Main Business and Markets Served
-
11.8.4 Gradalis RNAi for Therapeutic Consumption Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Quark Pharmaceuticals
-
11.9.1 Quark Pharmaceuticals Company Details
-
11.9.2 Quark Pharmaceuticals RNAi for Therapeutic Consumption Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Quark Pharmaceuticals RNAi for Therapeutic Consumption Main Business and Markets Served
-
11.9.4 Quark Pharmaceuticals RNAi for Therapeutic Consumption Product Portfolio
-
11.9.5 Recent Research and Development Strategies
12 Global RNAi for Therapeutic Consumption Market Outlook by Types and Applications to 2028
-
12.1 Global RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global siRNA Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global miRNA Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global shRNA Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Cancer Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Cardiovascular Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global HBV Consumption Forecast and Growth Rate (2022-2028)
-
12.2.4 Global Other Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise RNAi for Therapeutic Consumption Market Analysis and Outlook to 2028
-
13.1 Global RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.2.2 Canada RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.2.3 Mexico RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.3.2 UK RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.3.3 Spain RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.3.4 Belgium RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.3.5 France RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.3.6 Italy RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.3.7 Denmark RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.3.8 Finland RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.3.9 Norway RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.3.10 Sweden RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.3.11 Poland RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.3.12 Russia RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.3.13 Turkey RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.4.2 Japan RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.4.3 India RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.4.4 South Korea RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.4.5 Pakistan RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.4.7 Indonesia RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.4.8 Thailand RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.4.9 Singapore RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.4.10 Malaysia RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.4.11 Philippines RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.4.12 Vietnam RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.5.2 Colombia RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.5.3 Chile RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.5.4 Argentina RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.5.5 Venezuela RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.5.6 Peru RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.5.8 Ecuador RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.6.2 Kuwait RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.6.3 Oman RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.6.4 Qatar RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.7.2 South Africa RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.7.3 Egypt RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.7.4 Algeria RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
-
13.8.2 New Zealand RNAi for Therapeutic Consumption Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of RNAi for Therapeutic Consumption
-
Figure of RNAi for Therapeutic Consumption Picture
-
Table Global RNAi for Therapeutic Consumption Import by Region (Top 10 Countries) (2017-2028)
-
Table Global RNAi for Therapeutic Consumption Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global siRNA Consumption and Growth Rate (2017-2022)
-
Figure Global miRNA Consumption and Growth Rate (2017-2022)
-
Figure Global shRNA Consumption and Growth Rate (2017-2022)
-
Figure Global Cancer Consumption and Growth Rate (2017-2022)
-
Figure Global Cardiovascular Consumption and Growth Rate (2017-2022)
-
Figure Global HBV Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global RNAi for Therapeutic Consumption Consumption by Country (2017-2022)
-
Table North America RNAi for Therapeutic Consumption Consumption by Country (2017-2022)
-
Figure United States RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Canada RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Mexico RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Table Europe RNAi for Therapeutic Consumption Consumption by Country (2017-2022)
-
Figure Germany RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure UK RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Spain RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Belgium RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure France RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Italy RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Denmark RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Finland RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Norway RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Sweden RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Poland RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Russia RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Turkey RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Table APAC RNAi for Therapeutic Consumption Consumption by Country (2017-2022)
-
Figure China RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Japan RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure India RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure South Korea RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Pakistan RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Indonesia RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Thailand RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Singapore RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Malaysia RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Philippines RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Vietnam RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Table South America RNAi for Therapeutic Consumption Consumption by Country (2017-2022)
-
Figure Brazil RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Colombia RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Chile RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Argentina RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Venezuela RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Peru RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Ecuador RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Table GCC RNAi for Therapeutic Consumption Consumption by Country (2017-2022)
-
Figure Bahrain RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Kuwait RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Oman RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Qatar RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Table Africa RNAi for Therapeutic Consumption Consumption by Country (2017-2022)
-
Figure Nigeria RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure South Africa RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Egypt RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure Algeria RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Table Oceania RNAi for Therapeutic Consumption Consumption by Country (2017-2022)
-
Figure Australia RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Figure New Zealand RNAi for Therapeutic Consumption Consumption and Growth Rate (2017-2022)
-
Table Mirna Therapeutics Company Details
-
Table Mirna Therapeutics RNAi for Therapeutic Consumption Sales, Price, Value and Gross Profit (2017-2022)
-
Table Mirna Therapeutics RNAi for Therapeutic Consumption Main Business and Markets Served
-
Table Mirna Therapeutics RNAi for Therapeutic Consumption Product Portfolio
-
Table RXi Pharmaceuticals Company Details
-
Table RXi Pharmaceuticals RNAi for Therapeutic Consumption Sales, Price, Value and Gross Profit (2017-2022)
-
Table RXi Pharmaceuticals RNAi for Therapeutic Consumption Main Business and Markets Served
-
Table RXi Pharmaceuticals RNAi for Therapeutic Consumption Product Portfolio
-
Table Sirnaomics Company Details
-
Table Sirnaomics RNAi for Therapeutic Consumption Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sirnaomics RNAi for Therapeutic Consumption Main Business and Markets Served
-
Table Sirnaomics RNAi for Therapeutic Consumption Product Portfolio
-
Table miRagen Therapeutics Company Details
-
Table miRagen Therapeutics RNAi for Therapeutic Consumption Sales, Price, Value and Gross Profit (2017-2022)
-
Table miRagen Therapeutics RNAi for Therapeutic Consumption Main Business and Markets Served
-
Table miRagen Therapeutics RNAi for Therapeutic Consumption Product Portfolio
-
Table Alnylam Pharmaceuticals Company Details
-
Table Alnylam Pharmaceuticals RNAi for Therapeutic Consumption Sales, Price, Value and Gross Profit (2017-2022)
-
Table Alnylam Pharmaceuticals RNAi for Therapeutic Consumption Main Business and Markets Served
-
Table Alnylam Pharmaceuticals RNAi for Therapeutic Consumption Product Portfolio
-
Table Dicerna Pharmaceuticals Company Details
-
Table Dicerna Pharmaceuticals RNAi for Therapeutic Consumption Sales, Price, Value and Gross Profit (2017-2022)
-
Table Dicerna Pharmaceuticals RNAi for Therapeutic Consumption Main Business and Markets Served
-
Table Dicerna Pharmaceuticals RNAi for Therapeutic Consumption Product Portfolio
-
Table Arrowhead Company Details
-
Table Arrowhead RNAi for Therapeutic Consumption Sales, Price, Value and Gross Profit (2017-2022)
-
Table Arrowhead RNAi for Therapeutic Consumption Main Business and Markets Served
-
Table Arrowhead RNAi for Therapeutic Consumption Product Portfolio
-
Table Gradalis Company Details
-
Table Gradalis RNAi for Therapeutic Consumption Sales, Price, Value and Gross Profit (2017-2022)
-
Table Gradalis RNAi for Therapeutic Consumption Main Business and Markets Served
-
Table Gradalis RNAi for Therapeutic Consumption Product Portfolio
-
Table Quark Pharmaceuticals Company Details
-
Table Quark Pharmaceuticals RNAi for Therapeutic Consumption Sales, Price, Value and Gross Profit (2017-2022)
-
Table Quark Pharmaceuticals RNAi for Therapeutic Consumption Main Business and Markets Served
-
Table Quark Pharmaceuticals RNAi for Therapeutic Consumption Product Portfolio
-
Figure Global siRNA Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global miRNA Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global shRNA Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Cardiovascular Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global HBV Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global RNAi for Therapeutic Consumption Consumption Forecast by Country (2022-2028)
-
Table North America RNAi for Therapeutic Consumption Consumption Forecast by Country (2022-2028)
-
Figure United States RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe RNAi for Therapeutic Consumption Consumption Forecast by Country (2022-2028)
-
Figure Germany RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure France RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC RNAi for Therapeutic Consumption Consumption Forecast by Country (2022-2028)
-
Figure China RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure India RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Table South America RNAi for Therapeutic Consumption Consumption Forecast by Country (2022-2028)
-
Figure Brazil RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC RNAi for Therapeutic Consumption Consumption Forecast by Country (2022-2028)
-
Figure Bahrain RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa RNAi for Therapeutic Consumption Consumption Forecast by Country (2022-2028)
-
Figure Nigeria RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania RNAi for Therapeutic Consumption Consumption Forecast by Country (2022-2028)
-
Figure Australia RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand RNAi for Therapeutic Consumption Consumption Forecast and Growth Rate (2022-2028)
-
